×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

 

Preventing Infections in Cancer Patients Program to Launch Innovative Tools to Improve Patient-Provider Conversations

CDC  Foundation Program, Supported by Amgen, Will Launch New Virtual Simulation Mobile  Apps and Spanish-Language Website This Summer

Initiated  in 2009, the Program is Instrumental in Providing Key Resources for Patients,  Caregivers and Healthcare Professionals to Improve Infection Control During  Cancer Treatment

ATLANTA (June 5th, 2018) — The CDC Foundation and Amgen today announced several new  initiatives that will be available this summer as part of the Preventing  Infections in Cancer Patients (PICP) program. The PICP program has been  supported by Amgen and led by the Centers for Disease Control and Prevention  (CDC) and the CDC Foundation since the program’s launch in 2009. The PICP  program is instrumental in providing information, action steps and tools to  patients, caregivers and healthcare providers to help reduce the risk of  developing life-threatening infections during cancer treatment.

PICP initiatives launching this  summer include the CDC Foundation’s first virtual simulation tools, which have  great potential to educate patients and improve conversations between patients  and providers about infection risks during chemotherapy. These tools will be  available online and as free mobile apps.

One of the most common and  potentially life-threatening side effects of chemotherapy is neutropenia, which  may lead to hospitalization, disruption in chemotherapy schedules and even  death. Yet when cancer patients are going through chemotherapy treatments, they  are often so overwhelmed with their diagnosis and treatment plan that it can be  difficult for them to hear or remember conversations about infection risk  during chemotherapy. See a preview here of the new simulation tool for  oncology providers that includes a role-play conversation with a fully animated  and emotionally responsive virtual patient and provider.

At the heart of the PICP program is  a belief that every patient should have information tailored to their needs. To  meet this goal, a Spanish-language version of the website will also be created to  support the Hispanic community.

“We are grateful to Amgen for their  support of this important effort to help protect cancer patients,” said Judith  Monroe, MD, president and CEO of the CDC Foundation. ”A diagnosis of cancer can  be overwhelming, but thanks to this partnership we are helping patients learn  how to lower their infection risks when they’re going through chemotherapy.”

According to CDC, infections that  are linked to neutropenia are some of the most serious side effects of  chemotherapy. Based on the latest data available from 2012, more than 108,419  adults and children in the United States with cancer were hospitalized because  of neutropenia.

“Treatment with chemotherapy can  lead to a serious decrease in white blood cells, putting cancer patients at a  higher risk for infection and potentially causing dangerous complications that  add undue burden for patients, caregivers and health systems,” said Robert  Cuddihy, MD, vice president, head of US Medical at Amgen.

The PICP program has achieved a  number of milestones since its launch. In 2017 alone, the PICP  website had 86,000 unique visitors. Also, PICP resources have been  downloaded, received or viewed nearly two million times following efforts to  promote the program from CDC and the CDC Foundation. Importantly, recent  surveys reflect a 25 percent increase in patients and caregivers’ understanding  of neutropenia after visiting the PICP website.

“Strategic partnerships are key in  realizing our mission to make a difference in patient’s lives. Our long-term  partnership with the CDC Foundation has allowed us to make a significant impact  in the lives of those undergoing chemotherapy and the caregivers supporting  them,” said Peter Juhn, MD, vice president, Global Value-Based Partnerships at  Amgen.

About The CDC  Foundation
The CDC Foundation helps the Centers for Disease Control and  Prevention (CDC) save and improve lives by unleashing the power of  collaboration between CDC, philanthropies, corporations, organizations and  individuals to protect the health, safety and security of America and the  world. The CDC Foundation is the sole entity authorized by Congress to mobilize  philanthropic partners and private-sector resources to support CDC’s critical  health protection mission. Since 1995, the CDC Foundation has launched approximately  1,000 programs and raised over $740 million. The CDC Foundation managed over  300 CDC-led programs in the United States and in more than 130 countries last  year. For more information, visit www.cdcfoundation.org.  Follow the Foundation on Twitter, FacebookLinkedIn and Instagram.

CONTACT: CDC Foundation
Claire Stinson, 404-443-1126, cstinson@cdcfoundation.org

About Amgen
Amgen is committed to unlocking  the potential of biology for patients suffering from serious illnesses by  discovering, developing, manufacturing and delivering innovative human  therapeutics. This approach begins by using tools like advanced human genetics  to unravel the complexities of disease and understand the fundamentals of human  biology.

Amgen focuses on areas of high  unmet medical need and leverages its biologics manufacturing expertise to  strive for solutions that improve health outcomes and dramatically improve  people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be the  world’s largest independent biotechnology company, has reached millions of  patients around the world and is developing a pipeline of medicines with  breakaway potential. 

For more  information, visit www.amgen.com and  follow us on www.twitter.com/amgen.

CONTACT: Amgen, Thousand Oaks
Kristen Neese, 805-313-8267 (Media)
Kristen Davis, 805-447-3008 (Media)
Arvind Sood, 805-447-1060 (Investors)